Trk Receptor
Tropomyosin related kinase receptor
Trk receptors are a family of three receptor tyrosine kinases (TrkA, TrkB, and TrkC), each of which can be activated by one or more of four neurotrophins-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).
TrkA, TrkB, and TrkC are transmembrane proteins that comprise the TRK receptor family. These receptor tyrosine kinases are expressed in human neuronal tissue, and play an essential role in both the physiology of development and function of the nervous system through activation by neurotrophins (NTs). The latter are specific ligands known as NGF for TrkA, BDGF, and NT-4/5 for TrkB and NT3 for TrkC, respectively.
The binding of the ligand to the receptor triggers the oligomerisation of the receptors and phosphorylation of specific tyrosine residues in the intracytoplasmic kinase domain. This event results into the activation of signal transduction pathways leading to proliferation, differentiation and survival in normal and neoplastic neuronal cells.
Trk Receptor Isoform Specific Products
All Product Categories
-
Trk Receptor Inhibitors
(151)
View all products
-
Trk Receptor Agonists
(13)
View all products
-
Trk Receptor Antagonists
(4)
View all products
-
Trk Receptor Activators
(24)
View all products
-
Trk Receptor Modulators
(4)
View all products
-
Trk Receptor Degraders
(6)
View all products
-
Trk Receptor Controls
(4)
View all products
-
Trk Receptor Ligands
(2)
View all products
-
Trk Receptor Related Products (224)
Related Products (224)
-
Antibodies (9)
-
Trk Receptor Isoform Comparison
-
Izenivetmab
0 ImagesCat. No.: HY-P99677CAS No.: 2447755-72-6Synonyms: ZTS-00075623Izenivetmab (ZTS-00075623) is an anti-NGFB IgG2κ monoclonal antibody. Izenivetmab shows anti-inflammatory and analgesic effects by targeting anti-nerve growth factor (NGF). Izenivetmab can be used for the research of osteoarthritis.
-
PF-06273340
0 ImagesPF-06273340 is a peripherally restricted pan-Trk inhibitor with IC50 values of 6, 4, 3 nM for TrkA, TrkB, and TrkC receptors. PF-06273340 binds in a DFG-out conformation, targeting less conserved kinase ligand binding domain regions outside the ATP binding pocket. PF-06273340 exhibits anti-hyperalgesic and analgesic effects. PF-06273340 can be used for the research of pain.
-
Fasinumab
0 ImagesSynonyms: REGN-475; SAR-164877Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies.
-
Cannflavin B
0 ImagesSynonyms: CanniflavoneCannflavin B is a flavonoid compound that can be isolated from Cannabis sativa L. Cannflavin B is inhibitors of PGE2 release (IC50: 0.7 μM), mPGES-1 (IC50: 3.7 μM), and 5-lipoxygenase. Cannflavin B has multiple activities such as anti-inflammatory, antioxidant, anti-glycation, anti-ferroptosis, anti-tumor, and anti-Leishmania (IC50: 14 μM). Cannflavin B can also inhibit the TrkB-BDNF signaling pathway.
-
DLK-IN-1
0 ImagesDLK-IN-1 (Compound 14) is an orally active, blood-brain barrier-penetrable and selective inhibitor of dual leucine zipper kinase (DLK, MAP3K12) with a Ki value of 3 nM. DLK-IN-1 inhibits Flt3, PAK4, STK33 and TrkA. DLK-IN-1 reduces p-c-Jun. DLK-IN-1 can be used in Alzheimer's disease research.
-
Zurletrectinib
0 ImagesSynonyms: ICP-723Zurletrectinib is a brain-penetrant, orally active TRK inhibitor (TRKA IC50 = 0.81 nM; TRKB IC50 = 0.145 nM; TRKC IC50 = 0.184 nM). Zurletrectinib exhibits stronger activity as a consequence of its augmented binding affinity for TRK kinases. Zurletrectinib exhibits higher activity against most TRK inhibitor resistance mutations (13 out of 18 mutations). Zurletrectinib can be used for the study of glioma.
-
Fulranumab
0 ImagesCat. No.: HY-P99200CAS No.: 902141-80-4
-
GNF-8625 monopyridin-N-piperazine hydrochloride
0 ImagesGNF-8625 monopyridin-N-piperazine hydrochloride (TRKi-2), a TRK inhibitor, which is from the patent WO 2020038415 A1.
-
Entrectinib-d8
0 ImagesSynonyms: NMS-E628-d8; RXDX-101-d8Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC50 values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice.
-
Utatrectinib
0 ImagesSynonyms: AZD-7451
-
2-Bromo-6-methoxynaphthalene
0 Images2-Bromo-6-methoxynaphthalene is an active intermediate in the production of anti-inflammatory agents like Naproxen and Nabumetone by Heck reaction. 2-Bromo-6-methoxynaphthalene has potential anti-inflammatory properties and Tyrosine-protein inhibitor properties. 2-Bromo-6-methoxynaphthalene can be used for the research of cancer.
-
ALK-IN-28
0 ImagesALK-IN-28 (compound 22) is an inhibitor of anaplastic lymphoma kinase (ALK).
